114 studies found for:    mozobil
Show Display Options
Rank Status Study
1 Completed
Has Results
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: AMD3100;   Drug: Mitoxantrone;   Drug: Etoposide;   Drug: Cytarabine
2 Completed
Has Results
AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts
Condition: Autologous Stem Cell Transplantation
Intervention: Drug: G-CSF plus plerixafor
3 Completed
Has Results
G-CSF and AMD3100 to Mobilize Stem Cells in Healthy Volunteers
Condition: Healthy
Intervention: Drug: AMD 3100 (Mozobil plerixafor)
4 Unknown  Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major
Condition: Beta-Thalassemia
Intervention: Drug: Mozobil
5 Recruiting Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
Conditions: High Grade Glioma: Glioblastoma (GBM);   High Grade Glioma: Gliosarcoma;   Anaplastic Astrocytoma (AA);   Anaplastic Oligodendroglioma (AO);   Mixed Anaplastic Oligoastrocytoma (AOA)
Interventions: Drug: Plerixafor;   Drug: Bevacizumab;   Procedure: Surgery
6 Completed
Has Results
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Conditions: Multiple Myeloma;   Lymphoma, Non-Hodgkin
Intervention: Drug: G-CSF Plus Plerixafor
7 Completed
Has Results
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Conditions: Non-Hodgkin Lymphoma;   Hodgkin Disease
Interventions: Drug: G-CSF plus plerixafor;   Biological: rituximab
8 Terminated
Has Results
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
Conditions: Multiple Myeloma;   Lymphoma, Non-Hodgkin's
Intervention: Drug: G-CSF plus plerixafor
9 Completed
Has Results
Alteration in Timing of Plerixafor Administration
Condition: Autologous Transplantation
Intervention: Drug: Plerixafor
10 Completed Study of AMD3100 (Plerixafor) and Rituximab in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Intervention: Drug: plerixafor
11 Completed
Has Results
Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment
Condition: Renal Impairment
Intervention: Drug: plerixafor
12 Completed Feasibility and Efficiency Study of Leukemic Cell Mobilization With Plerixafor Injection
Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor (mozobil)
13 Completed
Has Results
AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease
Condition: Hodgkin's Disease
Intervention: Drug: G-CSF Plus Plerixafor
14 Completed
Has Results
Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients
Conditions: Lymphoma, Non-Hodgkin;   Multiple Myeloma
Intervention: Drug: G-CSF Plus Plerixafor
15 Recruiting Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Plerixafor (AMD3100);   Drug: bortezomib
16 Completed Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma
Conditions: Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: AMD3100;   Drug: G-CSF;   Procedure: Apheresis
17 Unknown  Healthy Donor Study II - Comparing Plerixafor With G-CSF and Plerixafor
Condition: Malignant Lymphoma, Stem Cell Type
Interventions: Drug: Plerixafor (Mozobil);   Drug: Plerixafor + G-CSF
18 Terminated AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia
Conditions: Pediatric Acute Myeloblastic Leukemia, Relapsed;   Pediatric Acute Lymphoblastic Leukemia, Relapsed
Intervention: Drug: AMD3100
19 Completed
Has Results
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Granulocyte-colony stimulating factor (G-CSF);   Drug: Fixed Dose Plerixafor;   Drug: Weight-Based Plerixafor
20 Unknown  Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection
Conditions: Multiple Myeloma;   Non-Hodgkins Lymphoma
Intervention: Drug: Plerixafor

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years